PubMed · 15364438
Continuous antigenic stimulation system (CASS) as a new immunization strategy.
Abstract
Protection against diseases is mediated by a sustained immune response. Here, we describe a new immunization strategy. Mice implanted with encapsulated C2C12 myoblasts secreting human factor IX (hFIX) elicited a strong humoral response against the transgene, as compared to mice immunized with complete Freund's adjuvant (FA). Mice also had increasing IgG2a antibody titer, indicating a switch to a Th1 profile immune response. Mice developed strong hFIX-specific cytotoxic T lymphocytes (CTL) that was detectable 213 days after implantation, demonstrating the sustained immunity elicited by encapsulated cells. Here, we propose continuous antigenic stimulation system (CASS) as a novel immunization strategy with potential application in the design of novel vaccines.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Andrew Gomez-Vargas, Kenneth L Rosenthal, Mark R McDermott, Gonzalo Hortelano. 2004-09-28. Continuous antigenic stimulation system (CASS) as a new immunization strategy.. https://doi.org/10.1016/j.vaccine.2004.04.010
Cite the original work for its findings. Save a collection to share your selection of sources.